Thalidomide Pregnancy Prevention Programme
Women of ChildBearing Potential (WCBP) Risk Awareness Form

RISK AWARENESS FORM FOR COUNSELLING THE PATIENT TO ENSURE THE PATIENT IS FULLY INFORMED ABOUT THE SAFE USE OF THALIDOMIDE

This Risk Awareness Form is to assist you with counselling a patient before they commence thalidomide treatment in order to ensure it is used safely and correctly. It must be completed for each female patient of childbearing potential prior to the initiation of their thalidomide treatment. This form must be completed by a physician experienced in managing immunomodulatory drugs.

The purpose of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse drug reactions associated with the use of thalidomide. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of thalidomide as it is contraindicated in women of childbearing potential unless all terms of counselling are met.

The form should be retained with their medical records, and a photocopy provided to the patient. It is not a contract and does not absolve anybody from his/her responsibilities regarding the safe use of the product and prevention of foetal exposure.

Warning: Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects. Thalidomide must never be used by women who are pregnant, or by women who could become pregnant unless all the conditions of the Pregnancy Prevention Programme are met. The conditions of the Pregnancy Prevention Programme must be fulfilled for all male and female patients. If thalidomide is taken during pregnancy, it can cause severe, life-threatening birth defects or death to an unborn baby.

Patient Details

Patient First Name:

Patient Last Name:

Date of Birth:	DD	MM	YYYY

Counselling Date:	DD	MM	YYYY

Did you inform your patient

1) Of the expected teratogenic risk to the unborn child and the need to avoid foetal exposure.	Tick
2) That if she is pregnant or plans to be, she must not take thalidomide.	Tick
3) Of the need to avoid thalidomide during pregnancy and to apply effective contraceptive measures without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and at least 4 weeks after the end of treatment.	Tick
4) That if she needs to change or stop using her method of contraception she should inform: a) the physician prescribing her contraception that she is taking thalidomide b) the prescriber prescribing thalidomide that she has stopped or changed her method of contraception	Tick
5) Of the need for pregnancy tests (i.e., before treatment) at least every 4 weeks during treatment and after treatment	Tick
6) Of the need to stop thalidomide immediately upon suspicion of pregnancy.	Tick
7) Of the need to contact their prescriber immediately upon suspicion of pregnancy.	Tick
8) To not share the medicinal product with any other person.	Tick

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-THL-008_v.2.0

Pathfinder
Risk Management Platform

9) That they should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of thalidomide.	Tick
10) That they should return the unused capsules to the pharmacist at the end of treatment	Tick

Can you confirm your patient

1) Was referred to a contraceptive consultant, if required?	Yes	No
2) Is capable of complying with contraceptive measures?	Yes	No
3) Agreed to undergo pregnancy testing at least in 4 weekly intervals unless confirmed tubal sterilisation?	Yes	No
4) Had a negative pregnancy test before starting treatment even if absolute and continued abstinence?	Yes	No

Contraceptive Referral (if answered yes to question 1 above)

Contraceptive referral made on:	DD	MM	YYYY

Contraceptive consultation conducted on:	DD	MM	YYYY

Pregnancy Prevention

The patient has been established on one of the following for at least 4 weeks:

Implant	Tick
Levonorgestrel-releasing intrauterine system (IUS)	Tick
Medroxyprogesterone acetate depot	Tick
Tubal sterilisation	Tick
Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses	Tick
Ovulation inhibitory progesterone-only pills (i.e. desogestrel)	Tick
Committed to complete and absolute abstinence	Tick

Pregnancy Test

Date of last negative pregnancy test, prior to treatment initiation:	DD	MM	YYYY

TREATMENT FOR A WOMAN OF CHILDBEARING POTENTIAL CANNOT START UNTIL PATIENT IS ESTABLISHED ON AT LEAST ONE EFFECTIVE METHOD OF CONTRACEPTION FOR AT LEAST 4 WEEKS PRIOR TO INITIATION OF THERAPY OR COMMITS TO COMPLETE AND CONTINUED ABSTINENCE AND PREGNANCY TEST IS NEGATIVE!

Prescriber Confirmation

I have fully explained to the patient named above the nature, purpose and risks of the treatment associated with thalidomide, especially the risks to women of childbearing potential.

I will comply with all my obligations and responsibilities as the prescribing physician of thalidomide.

Prescriber First Name:

Prescriber Last Name:

Prescriber Signature:		Date:	DD	MM	YYYY

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-THL-008_v.2.0

Patient: please read thoroughly and initial the adjacent box if you agree with the statement

I understand that severe birth defects can occur with the use of thalidomide. I have been warned by my prescriber that any unborn baby has a high risk of birth defects and could even die if a woman is pregnant or becomes pregnant while taking thalidomide.	Patient Initials
I understand that I must not take thalidomide if I am pregnant or plan to become pregnant.	Patient Initials
I understand that I must use one effective method of contraception without interruption, for at least 4 weeks before starting treatment, throughout the entire duration of treatment and even in the case of dose interruptions, and for at least 4 weeks after the end of treatment or commit to absolute and continuous sexual abstinence confirmed on a monthly basis. An effective method of contraception must be initiated by an appropriately trained healthcare professional.	Patient Initials
I understand that if I need to change or stop my method of contraception, I will discuss this first with the physician prescribing my contraception method and the physician prescribing my thalidomide.	Patient Initials
I understand that before starting the thalidomide treatment I must have a medically supervised pregnancy test. I will then have a pregnancy test every 4 weeks during treatment, and a test at least 4 weeks after the end of treatment.	Patient Initials
I understand that I must immediately stop taking thalidomide and inform my treating prescriber immediately upon suspicion of pregnancy while taking this drug (including dose interruptions); or if I miss my menstrual period or experience any unusual menstrual bleeding; or think FOR ANY REASON that I may be pregnant.	Patient Initials
I understand that thalidomide will be prescribed ONLY for me. I must not share it with ANYONE.	Patient Initials
I have read the thalidomide Patient Brochure and understand the contents, including the information about other possible health problems (side effects) associated with the use of thalidomide.	Patient Initials
I know that I cannot donate blood while taking thalidomide (including dose interruptions) and for at least 7 days after stopping treatment.	Patient Initials
I understand that I must return any unused thalidomide to my pharmacy at the end of my treatment.	Patient Initials
I understand that even if I have amenorrhoea I must comply with advice on contraception.	Patient Initials

Patient Confirmation

I confirm that I understand and will comply with the requirements of the thalidomide Pregnancy Prevention Programme, and I agree that my prescriber can initiate my treatment with thalidomide.

I understand that in order to receive thalidomide as part of the medical care and treatment that I am receiving, my personal data will be collected and processed by the NHS and the relevant Marketing Authorisation Holder (i.e. the supplier of thalidomide) and their processors, HealthBeacon plc and Pharmacare Group Ltd. I further understand that my personal data will be processed and retained in accordance with the relevant party's privacy policy, which can be found on their website.

Patient Signature:	

Date:	DD	MM	YYYY

Statement of the interpreter (where appropriate)

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-THL-008_v.2.0

I have interpreted the information above to the patient/parent to the best of my ability and in a way in which I believe she/he/they can understand. She/he/they agree to follow the necessary precautions to prevent an unborn child being exposed to thalidomide.

Interpreter Signature:			**Name:** (print)	

Date:	DD	MM	YYYY

For further information, please refer to the Summary of Product Characteristics (SmPC) for the respective medicinal product from the relevant Marketing Authorisation Holders or refer to the MHRA www.mhra.gov.uk

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-THL-008_v.2.0